{"filing":{"accession_number":"0001104659-26-090064","cik":"0000894158","ticker":"TOVX","company_name":"Theriva Biologics, Inc.","form":"8-K","filing_date":"2026-08-04","report_date":"2026-08-03","primary_document":"tm2619846d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/894158/000110465926090064/tm2619846d1_8k.htm"},"events":[{"id":23820,"run_id":21545,"accession_number":"0001104659-26-090064","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"Theriva Biologics held its Annual Meeting of stockholders on August 3, 2026, at which stockholders voted on six proposals: election of four directors, ratification of the auditor, Amendment No. 4 to the 2020 Stock Incentive Plan (increasing authorized shares from 4.5 million to 6.5 million), a charter amendment to increase authorized common stock, approval of warrant exercise issuance, and meeting adjournment. All six proposals passed.","company_name":"Theriva Biologics, Inc.","ticker":"TOVX","filing_date":"2026-08-04","form":"8-K","submitted_at":null,"items":[{"id":24157,"accession_number":"0001104659-26-090064","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure reports stockholder approval of Amendment No. 4 to the 2020 Stock Incentive Plan, increasing the authorized share pool from 4.5 million to 6.5 million shares. This is a compensatory arrangement amendment affecting the Company's ability to grant equity awards to officers and directors, which is a material governance and compensation matter requiring 8-K disclosure under Item 5.02(e).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:19:52.422398+00:00","company_name":"","ticker":null,"filing_date":""},{"id":24158,"accession_number":"0001104659-26-090064","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure reports the final voting results from Theriva Biologics' August 3, 2026 Annual Meeting of stockholders on six proposals: election of four directors, auditor ratification, amendment to the 2020 Stock Incentive Plan (increasing authorized shares from 4.5M to 6.5M), charter amendment to increase authorized common stock, approval of warrant exercise issuance, and meeting adjournment. All proposals passed. This is a textbook shareholder_vote_results event, and the outcomes—particularly the stock incentive plan expansion and warrant issuance approval—are material to investors' assessment of capital structure and dilution risk.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:19:52.422398+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":24157,"accession_number":"0001104659-26-090064","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure reports stockholder approval of Amendment No. 4 to the 2020 Stock Incentive Plan, increasing the authorized share pool from 4.5 million to 6.5 million shares. This is a compensatory arrangement amendment affecting the Company's ability to grant equity awards to officers and directors, which is a material governance and compensation matter requiring 8-K disclosure under Item 5.02(e).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:19:52.422398+00:00","company_name":"Theriva Biologics, Inc.","ticker":"TOVX","filing_date":"2026-08-04"},{"id":24158,"accession_number":"0001104659-26-090064","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure reports the final voting results from Theriva Biologics' August 3, 2026 Annual Meeting of stockholders on six proposals: election of four directors, auditor ratification, amendment to the 2020 Stock Incentive Plan (increasing authorized shares from 4.5M to 6.5M), charter amendment to increase authorized common stock, approval of warrant exercise issuance, and meeting adjournment. All proposals passed. This is a textbook shareholder_vote_results event, and the outcomes—particularly the stock incentive plan expansion and warrant issuance approval—are material to investors' assessment of capital structure and dilution risk.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:19:52.422398+00:00","company_name":"Theriva Biologics, Inc.","ticker":"TOVX","filing_date":"2026-08-04"}]}